Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553228 | 0.88 | ALDH1A1 (0.46) | FLT1KDRSIRT2YAP1 | |
| SCHEMBL20552711 | 0.87 | FLT1 (0.47) | FLT1KDRSIRT2TEAD1YAP1 | |
| SCHEMBL20552685 | 0.81 | TEAD1 (0.46) | FLT1KDREPHX2TEAD1YAP1 | |
| SCHEMBL21765173 | 0.80 | MAPK14 (0.43) | FLT1KDRMDM2ABCG2MAPK14 | |
| SCHEMBL21764712 | 0.80 | PDK2 (0.50) | NAMPT | |
| SCHEMBL20552643 | 0.79 | ABCG2 (0.47) | HDAC6ABCG2TAS2R14 | |
| SCHEMBL20552425 | 0.79 | TEAD1 (0.38) | FLT1KDREPHX2TEAD1YAP1 | |
| SCHEMBL25787879 | 0.78 | NAMPT (0.37) | FLT1KDRSIRT2HDAC3HDAC4 | |
| SCHEMBL20552661 | 0.78 | BRAF (0.42) | EPHX2TEAD1YAP1ABCG2TAS2R14 | |
| SCHEMBL20552347 | 0.75 | ABCG2 (0.46) | KDRABCG2TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| CN-111132673-A | Non-fused tricyclic compounds | 维瓦斯治疗公司 | 2020-05-08 | — | — | CN | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | FLT1 2930/4885KDR 1806/4885MDM2 296/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | FLT1 2930/4885KDR 1806/4885MDM2 296/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | FLT1 4483/4885KDR 4727/4885MDM2 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.